201 related articles for article (PubMed ID: 25245580)
1. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
Zheng Q; Wu H; Yu Q; Kim DH; Lipton JH; Angelini S; Soverini S; Vivona D; Takahashi N; Cao J
Pharmacogenomics J; 2015 Apr; 15(2):127-34. PubMed ID: 25245580
[TBL] [Abstract][Full Text] [Related]
2. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
[TBL] [Abstract][Full Text] [Related]
4. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Ali MA; Elsalakawy WA
Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
[TBL] [Abstract][Full Text] [Related]
6. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
[TBL] [Abstract][Full Text] [Related]
7. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
8. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
[TBL] [Abstract][Full Text] [Related]
9. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
10. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Singh O; Chan JY; Lin K; Heng CC; Chowbay B
PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
[TBL] [Abstract][Full Text] [Related]
12. Impact of
Dalle Fratte C; Polesel J; Gagno S; Posocco B; De Mattia E; Roncato R; Orleni M; Puglisi F; Guardascione M; Buonadonna A; Toffoli G; Cecchin E
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834713
[TBL] [Abstract][Full Text] [Related]
13. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
Zu B; Li Y; Wang X; He D; Huang Z; Feng W
Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
[TBL] [Abstract][Full Text] [Related]
14. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
15. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
16. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
17. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.
Dessilly G; Panin N; Elens L; Haufroid V; Demoulin JB
Sci Rep; 2016 Jul; 6():29559. PubMed ID: 27405085
[TBL] [Abstract][Full Text] [Related]
18. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
19. Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients.
Rinaldi I; Nova R; Widyastuti R; Priambodo R; Instiaty I; Louisa M
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3331-3334. PubMed ID: 31759356
[TBL] [Abstract][Full Text] [Related]
20. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G
Haematologica; 2013 Feb; 98(2):193-200. PubMed ID: 22875622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]